Abstract
Chronic kidney disease-mineral bone disorder (CKD-MBD) after kidney transplantation is a mix of pre-existing disorders and new alterations. The final consequences are reflected fundamentally as abnormal mineral metabolism (hypercalcemia, hypophosphatemia) and bone alterations [high or low bone turnover disease (as fibrous osteitis or adynamic bone disease), an eventual compromise of bone mineralization, decrease bone mineral density and bone fractures]. The major cause of post-transplantation hypercalcemia is the persistence of severe secondary hyperparathyroidism, and treatment options include calcimimetics or parathyroidectomy. On turn, hypophosphatemia is caused by both the persistence of high blood levels of PTH and/or high blood levels of FGF23, with its correction being very difficult to achieve. The most frequent bone morphology alteration is low bone turnover disease, while high-turnover osteopathy decreases in frequency after transplantation. Although the pathogenic mechanisms of these abnormalities have not been fully clarified, the available evidence suggests that there are a number of factors that play a very important role, such as immunosuppressive treatment, persistently high levels of PTH, vitamin D deficiency and hypophosphatemia. Fracture risk is four-fold higher in transplanted patients compared to general population. The most relevant risk factors for fracture in the kidney transplant population are diabetes mellitus, female sex, advanced age (especially > 65 years), dialysis vintage, high PTH levels and low phosphate levels, osteoporosis, pre-transplant stress fracture and high doses or prolonged steroids therapy. Treatment alternatives for CKD-MBD after transplantation include minimization of corticosteroids, use of calcium and vitamin D supplements, antiresorptives (bisphosphonates or Denosumab) and osteoformers (synthetic parathyroid hormone). As both mineral metabolism and bone disorders lead to increased morbidity and mortality, the presence of these changes after transplantation has to be prevented (if possible), minimized, diagnosed, and treated as soon as possible.
Similar content being viewed by others
References
Wolf RA, Ashby VB, Milford EL, Ojo AO, Ettenger RE, Agodoa LY et al (1999) Comparison of mortality in all patients on dialysis, patients on dialysis awaiting transplantation, and recipients of a first cadaveric transplant. N Engl J Med 341(23):1725–1730
Torres A, Lorenzo V, Salido E (2002) Calcium metabolism and skeletal problems after transplantation. J Am Soc Nephrol 13:551–558
Weisinger JR, Carlini RG, Rojas E, Bellorin-Font E (2006) Bone disease after renal transplantation. Clin J Am Soc Nephrol 1:1300–1313
Kalantar-Zadeh K, Molnar MZ, Kovesdy CP, Mucsi I, Bunnapradist S (2012) Management of mineral and bone disorder after kidney transplantation. Curr Opin Nephrol Hypertens 21:389–403
Torres A, Torregrosa JV, Marcen R et al (2016) Mineral metabolism disorders, vertebral fractures and aortic calcifications in stable kidney transplant recipients: The role of gender (EMITRAL study). Nefrologia 36:255–267
Evenepoel P, Van der Bergh B, Naesens M, De Jonge H, Bammens B, Claes K et al (2009) Calcium metabolism in the early posttransplantation period. Clin J Am Soc Nephrol 4:665–672
van der Plas WY, Gomes Neto AW, Berger SP et al (2020) Association of time-updated plasma calcium and phosphate with graft and patient outcomes after kidney transplantation. Am J Transplant. https://doi.org/10.1111/ajt.16457
Torregrosa JV, Bergua C, Martínez de Osaba MJ, Oppenheimer F, Campistol JM (2009) Evolution of secondary hyperparathyroidism after kidney transplantation in patients receiving cinacalcet on diálisis. Transplant Proc 41:2396–2398
Evenepoel P, Sprangers B, Lerut E et al (2012) Mineral metabolism in renal transplant recipients discontinuing cinacalcet at the time of transplantation: a prospective observational study. Clin Transplant 26:393–402
Torres A, Rodríguez AP, Concepción MT, García S, Rufino M, Martín B et al (1998) Parathyroid function in long-term renal transplant patients: importance of pre-transplant PTH concentrations. Nephrol Dial Transplant 13:94–97
Bouquegneau A, Salam S, Delanaye P, Eastell R, Khwaja A (2016) Bone disease after kidney transplantation. Clin J Am Soc Nephrol 11:1282–1296
Evenepoel P (2013) Recovery versus persistence of disordered mineral metabolism in kidney transplant recipients. Semin Nephrol 33:191–203
Ozdemir FN, Afsar B, Akgul A, Usluogullari C, Akçay A, Haberal M (2006) Persistent hypercalcemia is a significant risk factor for graft dysfunction in renal transplantation recipients. Transplant Proc 38:480–482
Egbuna OI, Taylor JG, Bushinsky DA (2007) Elevated calcium phosphate product after renal transplantation is a risk factor for graft failure. Clin Transplant 21:558
Gwinner W, Suppa S, Mengel M, Hoy L, Kreipe HH, Haller H et al (2005) Early calcification of renal allografts detected by protocol biopsies: causes and clinical implications. Am J Transplant 5:1934–1941
Evenepoel P, Lerut E, Naesens M et al (2009) Localization, etiology and impact of calcium phosphate deposits in renal allografts. Am J Transplant 9:2470–2478
Torregrosa JV, Barros X (2013) Management of hypercalcemia after renal transplantation. Nefrologia 33:751–757
Serra AL, Schwarz AA, Wick FH (2005) Succesful treatment of hypercalcemia with cinacalcet in renal transplant recipients with persistent hyperparthyroidism. Nephrol Dial Transplant 20:1315–1317
Bergua C, Torregrosa JV, Cofán F, Oppenheimer F (2007) Cinacalcet for the treatment of hypercalcemia in renal transplanted patients with secondary hyperparathyroidism. Transplant Proc 39(7):2254–2255
Kruse AE, Eisenberger U, Frey FL, Mohaupt MG (2007) Effect of cinacalcet cessation in renal transplant recipients with persistent hyperparathyroidism. Nephrol Dial Transplant 22:2362–2365
Schwarz A, Rustien G, Merkel S, Radermacher J, Haller H (2007) Decreased renal transplant function after parathyroidectomy. Nephrol Dial Transplant 22:584–591
Yang RL, Freeman K, Reinke CE et al (2012) Tertiary hyperparathyroidism in kidney transplant recipients: characteristics of patients selected for different treatment strategies. Transplantation 94:70–76
Triponez F, Clark OH, Vanrenthergem Y, Evenepoel P (2008) Surgical treatment of persistent hyperparathyroidism after renal transplantation. Ann Surg 248:18–30
Cruzado JM, Moreno P, Torregrosa JV et al (2016) A randomized study comparing parathyroidectomy with cinacalcet for treating hypercalcemia in kidney allograft recipients with hyperparathyroidism. J AM Soc Nephrol 27:2487–2494
Torregrosa JV, Felez I, Fuser D (2010) Usefulness of imaging techniques in secondary hyperparathyroidism. Nefrologia 30:158–167
Chen J, Jia X, Kong X et al (2017) Total parathyroidectomy with autotransplantation versus subtotal parathyroidectomy for renal hyperparathyroidism: a systematic review and meta-analysis. Nephrology 22:388–396
Liu M-E, Qiu N-C, Zha S-L et al (2017) To assess the effects of parathyroidectomy (TPTX versus TPTX+AT) for secondary hyperparathyroidism in chronic renal failure: a systematic review and meta-analysis. Int J Surg 44:353–362
Fülöp T, Koch CA, Farah Musa AR et al (2018) Targeted surgical parathyroidectomy in end-stage renal disease patients and long-term metabolic control: a single-center experience in the current era. Hemodial Int 22:394–404
Levi M (2001) Posttransplant hypophosphatemia. Kidney Int 59:2377–2387
Seeherunvong W, Wolf M (2011) Tertiary excess of fibroblast growth factor 23 and hypophosphatemia following kidney transplantation. Pediatr Transplant 15:37–46
Barros X, Torregrosa JV, Martínez de Osaba MJ, Casals G, Paschoalin R, Durán CE et al (2012) EarlierdecreaseofFGF-23andless hypophosphatemiainpreemptivekidneytransplantrecipients. Transplantation 94:830–836
Evenepoel P, Meijers BK, de Jonge H, Naesens M, Bammens B, Claes K et al (2008) Recovery of hyperphosphatoninism and renal phosphorus wasting one year after successful renal transplantation. Clin J Am Soc Nephrol 3:1829–1836
Malluche HH, Monier-Faugere MC, Herberth J (2010) Bone disease after renal transplantation. Nat Rev Nephrol 6(32–40):9
Chadban S, Chan M, Fry R et al (2010) The CARI guideline Nutritional management of hypophosphatemia in adult kidney transplant recipients. Nephrology 15:S48-51
Caravaca F, Fernandez MA, Ruiz-Calero R et al (1998) Effectos of oral phosphorus supplementation on mineral metabolism of renal transplant recipients. Nephrol Dial Transplant 13:2605–2611
Ambühl PM, Meier D, Wolf B et al (1999) Metabolic aspects of phosphate replacement therapy for hypophosphatemia after renal transplantation: impact on muscular phosphate content, mineral metabolism and acid/base homeostasis. Am J Kidney Dis 34:875–883
Riella LV, Rennke HG, Grafals M et al (2011) Hypophosphatemia in kidney transplant recipients: report of acute phosphate nephropathy as a complication of therapy. Am J Kidney Dis 57:641–645
Balal M, Paydas S, Seyrek N et al (2005) Dipyridamole for renal phosphate leak in successfully renal transplanted hypophosphatemic patients. Clin Nephrol 63:87–91
Julian BA, Laskow DA, Dubovsky J, Dubovsky EV, Curtis JJ, Quarles LD (1991) Rapid loss of vertebral mineral density after renal transplantation. N Engl J Med 325:544–550
Evenepoel P, Behets GJ, Viaene L, D’Haese PC (2017) Bone histomorphometry in de novo renal transplant recipients indicates a further decline in bone resorption 1 year posttransplantation. Kidney Int 91:469–476
Marques IDB, Araujo M, Graciolli FG et al (2019) A randomized trial of zoledronic acid to prevent bone loss in the first year after kidney transplantation. J Am Soc Nephrol 30:355–365
Keronen S, Martola L, Finne P, Burton IS, Kroger H, Honkanen E (2019) Changes in bone histomorphometry after kidney transplantation. Clin J Am Soc Nephrol 14:894–903
Patel S, Kwan JT, McCloskey E, McGee G, Thomas G, Johnson D et al (2001) Prevalence and causes of low bone density and fractures in kidney transplant patients. J Bone Miner Res 16:1863–1870
Ketteler M, Block GA, Evenepoel P et al (2017) Executive summary of the 2017 KDIGO chronic kidney disease-mineral and bone disorder (CKD-MBD) guideline update: what’s changed and why it matters. Kidney Int 92(1):26–36
Torregrosa JV, Bover J, Cannata-Andia J et al (2011) Spanish society of nephrology recommendations for controlling mineral and bone disorder in chronic kidney disease patients. Nefrologia 31(suppl 1):3–32
Brandenburg VM, Politt D, Ketteler M, Fassbender WJ, Heussen N, Westenfeld R et al (2004) Early rapid loss followed by long-term consolidation characterizes the development of lumbar bone mineral density after kidney transplantation. Transplantation 77:1566–1571
Torregrosa JV, Campistol JM, Montesinos M, Fenollosa B, Pons F, Martínez de Osaba MJ et al (1995) Factorsinvolvedinthelossofbone mineral density after renal transplantation. Transplant Proc 27:2224–2225
O’Brien CA, Jia D, Plotkin LI, Bellido T, Powers CC, Stewart SA et al (2004) Glucocorticoids act directly on osteoblasts and osteocytes to induce their apoptosis and reduce bone formation and strength. Endocrinology 145:1835–1841
Aroldi A, Tarantino A, Montagnino G, Cesana B, Cocucci C, Ponticelli C (1997) Effects of three immunosuppressive regimens on vertebral bone density in renal transplant recipients. Transplantation 63:380–386
Singha UK, Jiang Y, Yu S, Luo M, Lu Y, Zhang J et al (2008) Rapamycin inhibits osteoblast proliferation and differentiation in MC3T3-E1 cells and primary mouse bone marrow stromal cells. J Cell Biochem 103:434–446
Kneissel M, Luong-Nguyen NH, Baptist M, Cortesi R, Zumstein- Mecker S, Kossida S et al (2004) Everolimus suppresses cancellous bone loss, bone resorption, and cathepsin K expression by osteoclasts. Bone 35:1144–1156
Bonarek H, Merville P, Bonarek M et al (1999) Reduced parathyroid functional mass after successful kidney transplantation. Kidney Int 56:642–649
Torregrosa JV, Fuster D, Duran CE et al (2015) Set point of calcium in severe secondary hyperparathyroidism is altered and does not change after successful kidney transplantation. Endocrine 48:709–711
Evenepoel P, Claes K, Kuypers D et al (2004) Natural history of parathyroid function andcalcium metabolism after kidney transplantation: a single-centre study. Nephrol Dial Transplant 19:1281–1287
Perrin P, Caillard S, Javier RM et al (2013) Persistent hyperparathyroidism is a major risk factor for fractures in the five years after kidney transplantation. Am J Transplant 13:2653–2663
Almond MK, Kwan JTC, Evans K, Cunningham J (1994) Loss of regional bone mineral density in the first 12 months following renal transplantation. Nephron 66:52–57
Carlini RG, Rojas E, Weisinger JR, Lopez M, Martinis R, Arminio A et al (2000) Bone disease in patients with long-term renal transplantation and normal renal function. Am J Kidney Dis 36:160–165
Roe SD, Porter CJ, Godber IM, Hosking DJ, Cassidy MJ (2005) Reduced bone mineral density in male renal transplant recipients: evidence for persisting hyperparathyroidism. Osteoporos Int 16:142–148
Abdelhadi M, Nordenstrom J (1998) Bone mineral recovery after parathyroidectomy in patients with primary and renal hyperparathyroidism. J Clin Endocrinol Metab 83:3845–3851
Bergua C, Torregrosa JV, Fuster D, Gutierrez-Dalmau A, Oppenheimer F, Campistol JM (2008) Effect of cinacalcet on hypercalcemia and bone mineral density in renal transplanted patients with secondary hyperparathyroidism. Transplantation 86:413–417
Rojas E, Carlini RG, Clesca P, Arminio A, Suniaga O, De Elguezabal K et al (2003) The pathogenesis of osteodystrophy after renal transplantation as detected by early alterations in bone remodeling. Kidney Int 63:1915–1923
Naylor KL, Li AH, Lam NN, Hodsman AB, Jamal SA, Garg AX (2013) Fracture risk in kidney transplant recipients: a systematic review. Transplantation 95:1461–1470
Sidibe A, Auguste D, Desbiens LC et al (2019) Fracture risk in dialysis and kidney transplanted patients: a systematic review. JBMR Plus 3:45–55
Evenepoel P, Claes K, Meijers B et al (2019) Bone mineral density, bone turnover markers, and incident fractures in de novo kidney transplant recipients. Kidney Int 95:1461–1470
Nikkel LE, Hollenbeak CS, Fox EJ, Uemura T, Ghahramani N (2009) Risk of fractures after renal transplantation in the United States. Transplantation 87(12):1846–1851
Akaberi S, Simonsen O, Lindergård B, Nyberg G (2008) Can DXA predict fractures in renal transplant patients? Am J Transplant 8(12):2647–2651
Buckley L, Humphrey MB (2018) Glucocorticoid-Induced Osteoporosis. N Engl J Med 379:2547–2556
De Sévaux RG, Hoitsma AJ, Corstens FH, Wetzels JF (2002) Treatment with vitamin D and calcium reduces bone loss after renal transplantation: a randomized study. J Am Soc Nephrol 13:1608–1614
Torres A, García S, Gómez A, González A, Barrios Y, Concepción MT et al (2004) Treatment with intermittent calcitriol and calcium reduces bone loss after renal transplantation. Kidney Int 65:705–712
Marcén R, del Castillo D, Capdevila L (2009) Achieving chronic kidney disease treatment targets in renal transplant recipients: results from a cross-sectional study in Spain. Transplantation 87(9):1340–1346
Cianciolo G, Galassi A, Capelli I et al (2016) Vitamin D in kidney transplant recipients: mechanisms and therapy. Am J Nephrol 43(6):397–407
Maraka S, Kennel KA (2015) Bisphosphonates for the prevention and treatment of osteoporosis. BMJ 351:h3783
Wang J, Yao M, Xu JH et al (2016) Bisphosphonates for prevention of osteopenia in kidney-transplant recipients: a systematic review of randomized controlled trials. Osteoporos Int 27:1683–1690
Torregrosa JV, Fuster D, Monegal A, Gentil MA, Bravo J, Guirado L et al (2011) Efficacy of low doses of pamidronate in osteopenic patients administered in the early post-renal transplant. Osteoporos Int 22(1):281–287
Torregrosa JV, Fuster D, Gentil MA, Marcen R, Guirado L, Zarraga S et al (2010) Open-label trial: effect of weekly risedronate immediately after transplantation in kidney recipients. Transplantation 89(12):1476–1481
Cummings SR, San Martin J, McClung MR et al (2009) Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Eng J Med 361:756–756
Jamal S, Ljunggren O, Stehman-Breen C, Cummings SR, McClung MR, Goemaere S et al (2011) Effects of denosumab on fractures and bone mineral density by level of kidney function. J Bone Miner Res 26(8):1829–1835
Bonani M, Frey D, Brockmann J et al (2016) Effect of twice-yearly denosumab on prevention of bone mineral density loss in de novo kidney transplant recipients: a randomized controlled trial. Am J Transplant 16:1882–1891
Bonani M, Frey D, de Rougemont O et al (2017) Infections in De novo kidney transplant recipients treated with the RANKL inhibitor denosumab. Transplantation 101:2139–2145
Palmer SC, Chung EY, McGregor DO et al (2019) Interventions for preventing bone disease in kidney transplant recipients. Cochrane Database Syst Rev. 10(10):CD005015
Lindsay R, Krege JH, Marin F, Jin L, Stepan JJ (2016) Teriparatide for osteoporosis importance of the full course. Osteoporos Int 27(8):2395–2410
Cejka D, Benesch T, Krestan C, Roschger P, Klaushofer K, Pietschmann P et al (2008) Effect of teriparatide on early bone loss after kidney transplantation. Am J Transplant 8:1864–1870
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Disclosure
Josep-Vicent Torregrosa has no conflict of interest, and Ana Carina Ferreira reports personal fees from Amgen and Vifor Pharma, outside the submitted work. David Cucchiari has no conflict of interest. Aníbal Ferreira reports personal fees, grants and participation in advisory boards from Abbvie, Astellas, Amgen, Baxter, Merck Sharp and Dhome, Mundipharma, Nephrocare-Fresenius Medical Care, Sanofi and Vifor Pharma, outside the submitted work.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Torregrosa, JV., Ferreira, A.C., Cucchiari, D. et al. Bone Mineral Disease After Kidney Transplantation. Calcif Tissue Int 108, 551–560 (2021). https://doi.org/10.1007/s00223-021-00837-0
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00223-021-00837-0